ELRIG has announced the keynote speakers for its ‘Advances in Cell-Based Screening 2026’ conference. Professor Hazel Screen (Queen Mary University of London) and Dr Dave Powell (Relation Therapeutics) will deliver the keynote presentations during the free-to-attend event, which takes place on 6 and 7 May at AstraZeneca in Gothenburg,… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Semarion was voted one of the SLAS2025 New Product Award winners. DDW’s Diana Spencer catches up with CEO and Co-founder Jeroen Verheyen to find out how the company has bridged the worlds of science and engineering. DS: Congratulations on being one of the SLAS2025 New Product Award winners. Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in high-throughput applications… Read More
A new App Note is now available for download entitled ‘Powering high-throughput drug screening with Scale Bio‘. Scale Bio’s ScalePlex technology and Single Cell RNA Sequencing Kit v1.1 are revolutionising drug discovery by making large-scale single cell sample and condition screening possible. Libraries from 384 drug conditions were prepared… Read More
Scale Bio’s ScalePlex technology and Single Cell RNA Sequencing Kit v1.1 are revolutionising drug discovery by making large-scale single cell sample and condition screening possible. Libraries from 384 drug conditions were prepared in just 1.5 days 90% reduction in processing time >80% cell recovery rate and >3000 unique transcripts per… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of… Read More
DDW Editor Reece Armstrong takes a look at some recent advances in screening that are helping scientists in the drug discovery process. Screening is an essential part of the drug discovery process in which researchers analyse large libraries of compounds in order to discover promising molecule that demonstrate a… Read More
A new App Note is now available for download entitled ‘Fcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment’. Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample,… Read More
Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample, which assesses compatibility with three essential ligands in compliance with regulatory standards. This Application Note covers: How to rapidly assess column elution… Read More
This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. The Libra portfolio includes three small molecule programmes, including their lead non-clinical programme targeting TRPML1 (based on… Read More
